Compare Biogen Inc (BIIB) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs PepsiCo, Inc. — how do they compare? Biogen Inc trades at $196 (market cap $28.34B), while PepsiCo, Inc. trades at $135.81 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 6.5× Biogen Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | PEP | |
|---|---|---|
Market Cap | $28.34B | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $170.44 |
52-Week Low | $122.68 | $135.35 |
Enterprise Value | $30.62B | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
PepsiCo (PEP) trades at $135.45, down 2.2% on the day, with a bearish technical signal from moving averages but oversold short-term RSI. The company reported revenue of $93.93B for 2025 and has beaten EPS estimates for three consecutive quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while institutional investors show mixed activity.
The stock offers a forward dividend yield near 4% and trades below the consensus price target of $159.27, suggesting potential upside. Risks include execution of the North American turnaround and margin pressure from pricing strategies. Analyst sentiment is cautious with a majority Hold rating, reflecting near-term uncertainty amid strategic shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
